Puma Biotechnology (PBYI)

$9.97 0.58 (5.50%)

14:21 EST PBYI Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 376.98M

PE Ratio -1.53

EPS -6.53

Volume (Avg. Vol.) 204,036

Day's Range 9.94 - 11.06

52-Week Range 5.50 - 14.14

Dividend & Yield N/A (N/A)

PBYI Stock Predictions, Articles, and Puma Biotechnology News

From InvestorPlace
From the Web

Puma Biotechnology Earnings: PBYI Stock Skyrockets on Q4 Results

By William White, InvestorPlace Writer Mar 1, 2019

Puma Biotechnology earnings for the fourth quarter of 2018 have PBYI stock soaring on Friday with a strong EPS and revenue beat.

5 of the Best Biotech Stocks to Buy Now

By Ian Bezek, InvestorPlace Contributor Feb 4, 2019

Biotech stocks are off to a hot start in 2019, and these five stocks, in particular, could be the next winners.

10 Biggest Stock Market Successes of 2017

By James Brumley, InvestorPlace Feature Writer Dec 12, 2017

The year isn't over yet, but these ten names have pretty much secured their place as 2017's biggest and best stories.

4 Biotech Stocks That More Than Doubled This Year

By Zacks Investment Research Sep 5, 2017

The biotech sector has been witnessing an uptrend this year with impressive performance in both the quarters. Shares of quite a few companies have more than dou...

10 Stocks Ready for a BIG Move – In Either Direction

By Vince Martin, InvestorPlace Contributor Jun 15, 2017

Investors have been relatively complacent, but it's only a matter of time before anxiety strikes again. And these stocks could go either way.

Finish Line Inc (FINL) and Puma Biotech Inc (PBYI) Lead 15 Notable Investor Filings

By Fintel Jun 6, 2017

13D and 13G filings are windows into activist investor activity. We focus on Finish Line and 14 other filings of note

Puma Biotechnology Inc (PBYI) Pops 60% on FDA Review

By Robert Martin, InvestorPlace Writer May 22, 2017

An FDA review of Puma Biotechnology's breast cancer drug neratinib had mercifully few fireworks, prompting a surge in PBYI stock.

4 Biotech Stocks That Could Be Rocked and Rolled This Month

By James Brumley, InvestorPlace Feature Writer May 4, 2017

If you own any of these biotech stocks (or are thinking about it), mark these four dates on your calendar. Things are going to get real interesting, real fast.